Statistics for Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Total visits

views
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial 0

Total visits per month

views
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0

File Visits

views
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonasaeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilatedintensive care unit patients a.pdf 1